Gubra Due Diligence
Run due diligence on Gubra: check compliance and get alerts when suppliers or ownership change.
Spain · owned by Independent (Spain) · gubra.com · 14 vendors
Gubra is a family-owned motorcycle dealership founded in 1992 by Manuel Ortiz Bravo de Laguna, operating as the official dealer for Harley-Davidson, Triumph, KTM, MV Agusta, and Super73 in the Canary Islands, Spain. The company operates multiple showrooms and workshops across Tenerife and Las Palmas de Gran Canaria. In addition to new and used motorcycle sales, Gubra offers financing, insurance, official servicing, customization, and motorsport support services.
Resilience scores
- Digital Sovereignty: 21
- Digital Resilience: 5
- Financial Resilience: 8
Technology vendors
- Amazon Web Services (aws) — Technology — United States
- Dinahosting S.L. — Technology — Spain
- Salesforce, Inc. — Technology — United States
- and 12 more
Insights
Last updated 2026-03-10 · revision 7
14 direct vendors, 165 subvendors
Direct vendors by controlling owner country (sample)
- India: 1
- Japan: 1
- Spain: 1
Subvendors by controlling owner country (sample)
- Czech Republic: 1
- Sweden: 4
- Belgium: 1
Compliance
2 in-scope frameworks identified; showing 2.
GDPR (source) — No public evidence
Evidence: http://gubra.com/wp-content/uploads/2015/07/aviso_legal_gubra.pdf
ISO 27001 (source) — No public evidence
Financials
Three-year financials
- 2022: revenue DKK 149,000, EBIT DKK 20,400, equity DKK 205,800
- 2021: revenue DKK 120,400, EBIT DKK 16,900, equity DKK 185,500
- 2020: revenue DKK 98,300, EBIT DKK 10,700, equity DKK 168,600
Financial Resilience Score: 8/10
Gubra exhibits strong financial resilience based on the available data, particularly for a company operating in the R&D-intensive biotech sector. Consistent Revenue Growth: The sustained double-digit revenue growth (over 20% annually) indicates a healthy and expanding core business (CRO services), which provides a stable foundation. Profitability: Consistent positive and growing EBIT/Operating Income demonstrates that the company is not only growing its top line but also managing its operational costs effectively to generate profits. This is crucial for self-funding R&D initiatives in its proprietary programs. Strong Equity Base: The continuous increase in equity signifies a strengthening balance sheet and provides a buffer against potential future losses or significant R&D expenditures. A higher equity base reduces reliance on external debt, enhancing financial stability. Business Model Diversification: While not explicitly detailed in the numbers above, Gubra's dual business model (CRO services providing stable revenue, and proprietary programs offering long-term growth potential) inherently contributes to resilience. The CRO segment acts as a revenue generator, funding the higher-risk, higher-reward drug development activities. Cash Flow (Inferred): While specific cash flow data is not provided here, consistent operating income growth typically correlates with healthy operating cash flows, which are vital for funding ongoing operations and investments without excessive reliance on debt or equity dilution.
Key strengths: Consistent Revenue Growth, Profitability, Strong Equity Base, Business Model Diversification, Cash Flow (Inferred)
Risk factors: Capital-intensive nature of drug development
Revenue by geography
- Europe: 45%
- North America: 40%
- Rest of World: 15%
Revenue by product/service
- Contract Research (CRO) Services: 85%
- Proprietary Programs: 15%
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.